People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

The debate over whether insurers should pay for GLP-1 drugs like Ozempic and Wegovy has revived a familiar American argument ...

Altimmune said on Friday its experimental liver disease drug led to weight loss and improved markers for scarring and health of the organ based on non-invasive tests after 48 weeks of treatment in a ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Altimmune said on Friday its experimental liver disease drug improved signs of scarring and ‍health of the organ after 48 weeks of treatment in a mid-stage study, sending the company's shares up more ...

Eli Lilly’s oral GLP-1RA, orforglipron, has offered significant weight maintenance benefits during a Phase III study in obesity. Image credit: ChrisStock82 via Shutterstock.com. Eli Lilly’s oral ...

In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine.

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

San Francisco biopharmaceutical company is testing GLP-1 drug on obese cats, but simpler solution exists, suggest professionals ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.